Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 24 min ago
PreprintCC BY-NDbioRxiv

Cancer-associated mutations reconfigure dynamical responses in EGFR kinase

  1. 1University of Bristol

Abstract

The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a fundamental role in regulating cellular proliferation, survival, and differentiation. EGFR's kinase domain catalyses the autophosphorylation that drives downstream signalling and is a known hotspot for cancer-associated mutations. Such substitutions often enhance receptor activation, driving oncogenesis and therapeutic resistance, with major implications for prognosis and treatment choice; consequently, a detailed understanding of this domain's functional dynamics, and how mutations reshape them, is essential. Here, we apply dynamical-nonequilibrium molecular dynamics (D-NEMD) simulations to probe how changes at the ATP-binding site are transmitted throughout the kinase domain, ultimately shaping the behaviour of distal regions in the wild-type protein and in two of the most clinically observed non-small cell lung cancer variants, L858R and L858R+T790M. D-NEMD reveals previously uncharacterised communication networks linking the ATP pocket to key functional motifs, including the P-loop, C-helix, hinge region, activation loop, and F-helix, showing the intricate allosteric connectivity within this domain. Notably, numerous cancer-related mutation sites, despite being distant from the ATP site, map onto or lie close to these communication pathways, indicating that D-NEMD simulations can identify functionally relevant allosteric positions and potential mutation sites in EGFR. Our simulations further reveal that the two variants rewire EGFR's internal signal propagation network in distinct ways: L858R diminishes the transmission of structural changes to distal regions of the C-lobe, whereas introducing T790M in addition to L858R partially restores wild-type-like behaviour through compensatory rerouting of early-stage dynamical pathways.

Related

  1. Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer
    Wei-Chung Shia, Chien-Te Hsieh, Po-Chih Yang +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral biochemistryCrossrefEurope PMC
  2. Exosomal circ_0000387 Is Associated With Ovarian Cancer Metastatic Regulation Through IGF2BP3‐Related Signalling and Endothelial VWF Responses
    Yulian Xie, Peijun Shen, Hailin Chen +2
    Journal of Biochemical and Molecular ToxicologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  3. Cell Painting Identifies Phenotypic Clusters Associated with Anticancer Drug Responses in OVCAR-3 Ovarian Cancer Cells
    Vladimir E. Popov, Velemir S. Lavrinenko, Ekaterina V. Litau +6
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textBiophysicsCrossrefEurope PMC
  4. Targeting cancer-specific mutations with RNA-triggered chromatin shredding
    Jingkun Zeng, Zhiyuan Cheng, Huadong Chen +22
    NaturePeer-reviewedLicence not stated9 citedMolecular biology & gene regulationOpenAlex
  5. Sequence space exploration in SHP2: mechanistic insights from disease-associated mutations
    Anne E. van Vlimmeren, Ziyuan Jiang, Devon A. Semoy +1
    Biochemical JournalPeer-reviewedCC BY 4.0Full textStructural biologyPMC
BibTeX
@misc{tulli2026cancerassociated,
  title = {{Cancer-associated mutations reconfigure dynamical responses in EGFR kinase}},
  author = {L. Tulli and A. Lodola and A. J. Mulholland and A. S. F. Oliveira},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.08.757680},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.08.757680v1},
  note = {CC BY-ND},
}
RIS
TY  - UNPB
TI  - Cancer-associated mutations reconfigure dynamical responses in EGFR kinase
AU  - L. Tulli
AU  - A. Lodola
AU  - A. J. Mulholland
AU  - A. S. F. Oliveira
PY  - 2026
DA  - 2026/10/08
PB  - bioRxiv
DO  - 10.64898/2026.10.08.757680
UR  - https://www.biorxiv.org/content/10.64898/2026.10.08.757680v1
AB  - The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a fundamental role in regulating cellular proliferation, survival, and differentiation. EGFR's kinase domain catalyses the autophosphorylation that drives downstream signalling and is a known hotspot for cancer-associated mutations. Such substitutions often enhance receptor activation, driving oncogenesis and therapeutic resistance, with major implications for prognosis and treatment choice; consequently, a detailed understanding of this domain's functional dynamics, and how mutations reshape them, is essential. Here, we apply dynamical-nonequilibrium molecular dynamics (D-NEMD) simulations to probe how changes at the ATP-binding site are transmitted throughout the kinase domain, ultimately shaping the behaviour of distal regions in the wild-type protein and in two of the most clinically observed non-small cell lung cancer variants, L858R and L858R+T790M. D-NEMD reveals previously uncharacterised communication networks linking the ATP pocket to key functional motifs, including the P-loop, C-helix, hinge region, activation loop, and F-helix, showing the intricate allosteric connectivity within this domain. Notably, numerous cancer-related mutation sites, despite being distant from the ATP site, map onto or lie close to these communication pathways, indicating that D-NEMD simulations can identify functionally relevant allosteric positions and potential mutation sites in EGFR. Our simulations further reveal that the two variants rewire EGFR's internal signal propagation network in distinct ways: L858R diminishes the transmission of structural changes to distal regions of the C-lobe, whereas introducing T790M in addition to L858R partially restores wild-type-like behaviour through compensatory rerouting of early-stage dynamical pathways.
ER  -